x
- Home
- Diabetes Models
- In Vivo Models of Diabetes Mellitus
- In Vitro Models of Diabetes Mellitus
- Diabetes Drug R&D Services
- Therapeutic Areas
- Virtual Booth
- Company
Enzymes represent an ideal target for antidiabetic drug development. Ace Therapeutics specializes in traditional and innovative targets related to diabetes, offering antidiabetic drug discovery services targeting enzymes. Our professional drug discovery team can provide one-stop service from diabetes target identification, antidiabetic drug screening, preclinical efficacy and safety assessment.
Enzymes are another important class of targets for the development of novel antidiabetic drugs. These enzymes play important roles in diabetes-related regulation of glucose homeostasis, energy regulation, and metabolic regulation. α-Glucosidase (AG) is one of the important diabetes targets. AG catalyzes carbohydrate hydrolysis thus enabling glucose absorption in the brush border site of the small intestine. AG inhibitors are one of the efficient oral antidiabetic drugs for controlling postprandial hyperglycemia and its detrimental physiological complications. The discovery and validation of these targets hold great promise and opportunity for the development of innovative therapies for diabetes and its complications.
The following is a list of enzymes that can be used as targets for antidiabetic drug development and their role in diabetes mechanism:
Ace Therapeutics provides one-stop services for antidiabetic drug development by targeting diabetes-related enzymes. Our experienced experts have in-depth knowledge of the specific mechanisms by which these enzymes are involved in diabetes-related processes. We provide customized strategies to discover effective enzyme inhibitors, antagonists or agonists to be used as innovative antidiabetic drugs based on the target of interest.
Ace Therapeutics helps clients discover innovative therapeutic targets for diabetes using advanced genomics and target validation technologies. Our objective is to assist our clients in identifying novel targets that can be leveraged as breakthroughs in the development of a new generation of antidiabetic drugs.
Ace Therapeutics provides antidiabetic drug screening services based on well-defined targets. We can create customized screening systems based on the target of interest and use high-throughput screening technology to help clients rapidly identify potential candidate antidiabetic molecules. In addition, we fully test the effect of the antidiabetic molecule candidate on the target and optimize its structure and activity based on the results.
We select appropriate in vivo and in vitro models for a comprehensive assessment of the efficacy of antidiabetic drug candidates. These tests include, but are not limited to, evaluation of the impact of the drug candidates on blood glucose, lipids, insulin secretion and related pathways.
We provide comprehensive pharmacokinetic analyses aimed at obtaining information related to efficacy, safety and dose-response of antidiabetic drugs.
We provide comprehensive preclinical safety assessment services using animal models. The resulting data can reflect information about the risks and potential adverse effects of antidiabetic drug candidates, thus supporting antidiabetic drug development.
Ace Therapeutics is committed to applying our expertise in diabetes targeting and preclinical drug discovery to efficiently drive our clients' antidiabetic drug development programs. Please contact us to learn more about our enzyme-targeted antidiabetic drug development services. We are available to answer queries you may have and provide you with a prompt response.
Ace Therapeutics has a team of experts in the field of endocrine and metabolic research, aiming to provide innovative preclinical contract research solutions to cope with diabetes and its complications. We provide customized solutions and technical support, enabling the transformation of promising concepts into innovative treatments, thus accelerating the drug development process of diabetes.
